
Deerfield Management is a healthcare-focused investment firm that has been actively investing in the industry for over two decades.
The firm's management portfolio includes a diverse range of companies, from biotechnology and pharmaceuticals to medical devices and diagnostics.
Deerfield Management's funding activities are primarily focused on investing in private companies, with a strong emphasis on providing growth capital to emerging and established biopharma companies.
Deerfield Management's investment strategy is centered around partnering with innovative companies that have the potential to transform the healthcare landscape.
Funding and Investments
Deerfield Management has a history of closing large venture capital funds, with the Deerfield Healthcare Innovations Fund II closing at $840 million and the Deerfield Healthcare Innovations Fund III closing at over $600 million.
The funds will focus on investing in science startups related to new therapies and technology to improve the way healthcare is delivered to patients. Deerfield plans to collaborate with over 15 academic institutions to seed novel research.
On a similar theme: Frazier Healthcare Partners
Deerfield has a unique model that provides leverage to innovative companies and accelerates the benefit to patients. The firm also fully funds and manages the Deerfield Foundation, which has committed or invested over $49 million to global organizations working to improve healthcare to underserved children.
Deerfield has made significant investments in translational research initiatives, including a $130 million investment in Orchard Innovations, a company that will support a translational research initiative with the Weizmann Institute of Science.
Sells Melinta Therapeutics
Deerfield Management Company has sold its portfolio company Melinta Therapeutics.
Deerfield Management Company is an investment firm dedicated to advancing healthcare.
The sale was closed, marking the end of Deerfield's involvement with Melinta Therapeutics.
For another approach, see: B Capital
Closes $840M VC Fund
Deerfield Management recently closed its $840 million venture capital fund, the Deerfield Healthcare Innovations Fund II. This fund will focus on investing in science startups related to new therapies and technology to improve healthcare delivery to patients.

The fund plans to collaborate with more than 15 academic institutions to seed novel research. It also has arrangements with medtech incubators that it originated in partnership with two medical device companies.
Deerfield's work related to the fund will be primarily located at The Cure, an innovation campus in New York City. Early-stage startups will have access to The Cure's resources, including wet and dry labs, engineering, computing, and shared resources.
Deerfield's managing partner, James E. Flynn, emphasized the importance of supporting scientists and healthcare systems during these unprecedented times.
Historical 13F Filings
We've compiled all 13F filings since Q2 2013 for your convenience, allowing you to view historical portfolio positions for companies like Deerfield Management Company.
You can access these filings in our 13F section, where you'll find a comprehensive list of holdings that fall under 13F regulatory guidelines.
Our 13F section is a valuable resource for personal investment decisions, providing a wealth of information on historical portfolio positions and holdings.
A unique perspective: Ra Capital 13f
Frequently Asked Questions
What is the legal name for Deerfield Management?
The legal name for Deerfield Management is Deerfield Management Company, L.P. This is the official name registered for the company.
Featured Images: pexels.com


